More and more imaging researchers are starting to examine the potential of using fibroblast activation protein inhibitors (FAPI) to manage patients with suspected cardiovascular disease.
The BENEFIT-HF trial, scheduled to begin enrollment in the months ahead, could significantly increase the number of patients eligible for CVRx's Barostim therapy.
Shockwave Medical, now a part of Johnson & Johnson MedTech, sits at the top of the IVL market, but things are starting to get more competitive. Boston Scientific gained its own IVL system when it acquired Bolt Medical in 2025.
Gene-editing drugs have shown potential to treat a wide variety of diseases, and this will be one of the first in cardiovascular medicine to begin human trials.
The findings raise concerns about women who are planning on becoming pregnant and imaging-related radiation exposure in the weeks leading up to conception.
Biparametric prostate MRIs take significantly less time than multiparametric exams, as they do not include a contrast-enhanced sequence. This also makes the abbreviated exams more cost-friendly.
Using an advanced MRI technique, experts were able to measure tissue susceptibility and detect subtle variances in iron levels throughout different regions of the brain associated with memory.
Evaluating LVDF with echocardiography or AI-powered electrocardiography can help identify individuals at an increased risk of developing atrial fibrillation, according to new data presented at the ASE 36th Annual Scientific Sessions.
Reuters reported that 500 institutions are linked to the proposals. In total, $50 million is up for grabs as part of HHS’ Autism Data Science Initiative.
When patients present with STEMI-related cardiogenic shock, treatment with the Impella CP appears to make a positive impact that lasts for at least a decade.
